Cargando…
Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats
BACKGROUND: Preventing pulmonary vascular remodeling is a key strategy for pulmonary hypertension (PH). Causes of PH include pulmonary vasoconstriction and inflammation. This study aimed to determine whether cilostazol (CLZ), a phosphodiesterase-3 inhibitor, prevents monocrotaline (MCT)- and chronic...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605570/ https://www.ncbi.nlm.nih.gov/pubmed/34801000 http://dx.doi.org/10.1186/s12890-021-01710-4 |
_version_ | 1784602208299384832 |
---|---|
author | Ito, Toshikazu Zhang, Erquan Omori, Ayaka Kabwe, Jane Kawai, Masako Maruyama, Junko Okada, Amphone Yokochi, Ayumu Sawada, Hirofumi Mitani, Yoshihide Maruyama, Kazuo |
author_facet | Ito, Toshikazu Zhang, Erquan Omori, Ayaka Kabwe, Jane Kawai, Masako Maruyama, Junko Okada, Amphone Yokochi, Ayumu Sawada, Hirofumi Mitani, Yoshihide Maruyama, Kazuo |
author_sort | Ito, Toshikazu |
collection | PubMed |
description | BACKGROUND: Preventing pulmonary vascular remodeling is a key strategy for pulmonary hypertension (PH). Causes of PH include pulmonary vasoconstriction and inflammation. This study aimed to determine whether cilostazol (CLZ), a phosphodiesterase-3 inhibitor, prevents monocrotaline (MCT)- and chronic hypoxia (CH)-induced PH development in rats. METHODS: Fifty-one male Sprague–Dawley rats were fed rat chow with (0.3% CLZ) or without CLZ for 21 days after a single injection of MCT (60 mg/kg) or saline. Forty-eight rats were fed rat chow with and without CLZ for 14 days under ambient or hypobaric (air at 380 mmHg) CH exposure. The mean pulmonary artery pressure (mPAP), the right ventricle weight-to-left ventricle + septum weight ratio (RV/LV + S), percentages of muscularized peripheral pulmonary arteries (%Muscularization) and medial wall thickness of small muscular arteries (%MWT) were assessed. Levels of the endothelial nitric oxide synthase (eNOS), phosphorylated eNOS (peNOS), AKT, pAKT and IκB proteins in lung tissue were measured using Western blotting. Monocyte chemotactic protein (MCP)-1 mRNA in lung tissue was also assessed. RESULTS: mPAP [35.1 ± 1.7 mmHg (MCT) (n = 9) vs. 16.6 ± 0.7 (control) (n = 9) (P < 0.05); 29.1 ± 1.5 mmHg (CH) (n = 10) vs. 17.5 ± 0.5 (control) (n = 10) (P < 0.05)], RV/LV + S [0.40 ± 0.01 (MCT) (n = 18) vs. 0.24 ± 0.01 (control) (n = 10) (P < 0.05); 0.41 ± 0.03 (CH) (n = 13) vs. 0.27 ± 0.06 (control) (n = 10) (P < 0.05)], and %Muscularization and %MWT were increased by MCT injection and CH exposure. CLZ significantly attenuated these changes in the MCT model [mPAP 25.1 ± 1.1 mmHg (n = 11) (P < 0.05), RV/LV + S 0.30 ± 0.01 (n = 14) (P < 0.05)]. In contrast, these CLZ effects were not observed in the CH model. Lung eNOS protein expression was unchanged in the MCT model and increased in the CH model. Lung protein expression of AKT, phosphorylated AKT, and IκB was downregulated by MCT, which was attenuated by CLZ; the CH model did not change these proteins. Lung MCP-1 mRNA levels were increased in MCT rats but not CH rats. CONCLUSIONS: We found model differences in the effect of CLZ on PH development. CLZ might exert a preventive effect on PH development in an inflammatory PH model but not in a vascular structural change model of PH preceded by vasoconstriction. Thus, the preventive effect of CLZ on PH development might depend on the PH etiology. |
format | Online Article Text |
id | pubmed-8605570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86055702021-11-22 Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats Ito, Toshikazu Zhang, Erquan Omori, Ayaka Kabwe, Jane Kawai, Masako Maruyama, Junko Okada, Amphone Yokochi, Ayumu Sawada, Hirofumi Mitani, Yoshihide Maruyama, Kazuo BMC Pulm Med Research Article BACKGROUND: Preventing pulmonary vascular remodeling is a key strategy for pulmonary hypertension (PH). Causes of PH include pulmonary vasoconstriction and inflammation. This study aimed to determine whether cilostazol (CLZ), a phosphodiesterase-3 inhibitor, prevents monocrotaline (MCT)- and chronic hypoxia (CH)-induced PH development in rats. METHODS: Fifty-one male Sprague–Dawley rats were fed rat chow with (0.3% CLZ) or without CLZ for 21 days after a single injection of MCT (60 mg/kg) or saline. Forty-eight rats were fed rat chow with and without CLZ for 14 days under ambient or hypobaric (air at 380 mmHg) CH exposure. The mean pulmonary artery pressure (mPAP), the right ventricle weight-to-left ventricle + septum weight ratio (RV/LV + S), percentages of muscularized peripheral pulmonary arteries (%Muscularization) and medial wall thickness of small muscular arteries (%MWT) were assessed. Levels of the endothelial nitric oxide synthase (eNOS), phosphorylated eNOS (peNOS), AKT, pAKT and IκB proteins in lung tissue were measured using Western blotting. Monocyte chemotactic protein (MCP)-1 mRNA in lung tissue was also assessed. RESULTS: mPAP [35.1 ± 1.7 mmHg (MCT) (n = 9) vs. 16.6 ± 0.7 (control) (n = 9) (P < 0.05); 29.1 ± 1.5 mmHg (CH) (n = 10) vs. 17.5 ± 0.5 (control) (n = 10) (P < 0.05)], RV/LV + S [0.40 ± 0.01 (MCT) (n = 18) vs. 0.24 ± 0.01 (control) (n = 10) (P < 0.05); 0.41 ± 0.03 (CH) (n = 13) vs. 0.27 ± 0.06 (control) (n = 10) (P < 0.05)], and %Muscularization and %MWT were increased by MCT injection and CH exposure. CLZ significantly attenuated these changes in the MCT model [mPAP 25.1 ± 1.1 mmHg (n = 11) (P < 0.05), RV/LV + S 0.30 ± 0.01 (n = 14) (P < 0.05)]. In contrast, these CLZ effects were not observed in the CH model. Lung eNOS protein expression was unchanged in the MCT model and increased in the CH model. Lung protein expression of AKT, phosphorylated AKT, and IκB was downregulated by MCT, which was attenuated by CLZ; the CH model did not change these proteins. Lung MCP-1 mRNA levels were increased in MCT rats but not CH rats. CONCLUSIONS: We found model differences in the effect of CLZ on PH development. CLZ might exert a preventive effect on PH development in an inflammatory PH model but not in a vascular structural change model of PH preceded by vasoconstriction. Thus, the preventive effect of CLZ on PH development might depend on the PH etiology. BioMed Central 2021-11-20 /pmc/articles/PMC8605570/ /pubmed/34801000 http://dx.doi.org/10.1186/s12890-021-01710-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Ito, Toshikazu Zhang, Erquan Omori, Ayaka Kabwe, Jane Kawai, Masako Maruyama, Junko Okada, Amphone Yokochi, Ayumu Sawada, Hirofumi Mitani, Yoshihide Maruyama, Kazuo Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats |
title | Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats |
title_full | Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats |
title_fullStr | Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats |
title_full_unstemmed | Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats |
title_short | Model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats |
title_sort | model difference in the effect of cilostazol on the development of experimental pulmonary hypertension in rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605570/ https://www.ncbi.nlm.nih.gov/pubmed/34801000 http://dx.doi.org/10.1186/s12890-021-01710-4 |
work_keys_str_mv | AT itotoshikazu modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT zhangerquan modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT omoriayaka modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT kabwejane modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT kawaimasako modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT maruyamajunko modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT okadaamphone modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT yokochiayumu modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT sawadahirofumi modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT mitaniyoshihide modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats AT maruyamakazuo modeldifferenceintheeffectofcilostazolonthedevelopmentofexperimentalpulmonaryhypertensioninrats |